Levotonal

Calcium levofolinate, the active ingredient in Levotonal, is an antifolate presented as an injection solution for intravenous use. It provides a reduced folate cofactor that bypasses dihydrofolate reductase inhibition, thereby rescuing normal cells from the cytotoxic effects of antifolate chemotherapy and enhancing the activity of fluoropyrimidine agents in patients undergoing high‑dose methotrexate or 5‑fluorouracil‑based regimens.

GNH USA supplies Levotonal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant centres and pharmacies worldwide. Our distribution network ensures consistent quality and regulatory compliance across EU and global markets.

Levotonal is employed in oncology and supportive care to mitigate folate pathway disruption caused by antifolate chemotherapy. - Rescue therapy after high‑dose methotrexate: reduces methotrexate toxicity and allows safe continuation of chemotherapy. - Adjunct to 5‑fluorouracil‑based chemotherapy: enhances antitumor activity by stabilizing the active metabolite. - Prevention/treatment of folate deficiency: restores folate levels in patients with chemotherapy‑induced depletion.

Calcium levofolinate may be associated with several adverse reactions, most of which are related to the injection process or underlying chemotherapy.

Common Side Effects: - Nausea: mild to moderate nausea. - Fever: transient pyrexia. - Injection site reactions: erythema or discomfort. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate treatment. - Acute renal failure: rare kidney impairment. - Thromboembolic events: rare clot formation.

Before using Levotonal, clinicians should consider several safety measures. - Renal function: assess baseline creatinine and monitor during therapy. - Hepatic function: evaluate liver enzymes before administration. - Concurrent methotrexate: coordinate timing to avoid overlapping toxicity. - Pregnancy and lactation: use only if benefits outweigh risks, as safety data are limited. - Allergy history: screen for hypersensitivity to folate compounds. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Calcium levofolinate can interact with other medications that affect folate metabolism or methotrexate clearance.

Major Interactions (Avoid): - High-dose methotrexate: simultaneous administration may reduce rescue efficacy; schedule appropriately. - Antifolate agents (e.g., pemetrexed): may antagonize therapeutic effect.

Moderate Interactions (Monitor Closely): - NSAIDs: can increase methotrexate toxicity, indirectly affecting calcium levofolinate rescue. - Proton pump inhibitors: may alter renal clearance of methotrexate. - Sulfonamides: potential additive bone marrow suppression.